Agenus Inc. (AJ8)
FSX
Closed
Oct 7, 2026
Day's Range
6.6052 wk Range
2.30Overview - AJ8 - Agenus Inc.
Key Statistics
Valuation
Enterprise Value
309.54M
P/E (Trailing)
‪2.87‬
PEG Ratio
‪-0.02‬
Price / Sales (TTM)
‪2.55‬
Price / Book
‪-1.50‬
EV / EBITDA
‪8.68‬
Profitability
Gross Margin
‪57.24%‬
Profit Margin
‪69.34%‬
Operating Margin
‪32.71%‬
Return on Assets
‪12.53%‬
Return on Equity
‪0.03%‬
Ownership
Shares Outstanding
44.75M
Float
40.23M
Held by Insiders
‪6.23%‬
Held by Institutions
‪46.44%‬
Price stats
Beta
‪1.39‬
50-Day Avg
‪6.22‬
200-Day Avg
‪3.77‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - AJ8 - Agenus Inc.
Peers - AJ8 - Agenus Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- AJ8FSXAgenus Inc.338.71MMarket Cap+55.47%52-week change2.87P/E (Trailing)‪69.34%‬Profit Margin
- ANLFSXAnalog Devices Inc.179.11BMarket Cap+43.92%52-week change47.10P/E (Trailing)‪29.78%‬Profit Margin
- 0QFFSXModerna Inc.69.12BMarket Cap+87.76%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 64BFSXAstera Labs, Inc.53.43BMarket Cap+42.53%52-week change179.66P/E (Trailing)‪30.74%‬Profit Margin
- 1AEFSXargenx SE52.63BMarket Cap+28.29%52-week change36.62P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt50.36BMarket Cap+25.47%52-week change34.88P/E (Trailing)‪32.26%‬Profit Margin
- 42ZFSXRevolution Medicines, Inc.37.58BMarket Cap+78.78%52-week change-29.47P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - AJ8 - Agenus Inc.
About
Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer. Agenus develops a pipeline of checkpoint antibodies, immune modulators, and combination regimens designed to help the immune system recognize and attack tumors. Its current portfolio also includes…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
